Viki Forlano, MD
Family Medicine · San Angelo, TXNPI 1376547216
Payments from drug & device makers
Across 235 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- AstraZeneca$544
- GSK$493
- Lilly USA, LLC$385
- Johnson & Johnson$375
- AbbVie$264
- plus $2K from 30 others
What the payments were for
- Consulting fees$1,56028%
- Speaking & faculty fees$952%
- Food & beverage$3,83470%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $1,260 |
| AstraZeneca | 35 | $544 |
| GSK | 13 | $493 |
| Lilly USA, LLC | 22 | $385 |
| Johnson & Johnson | 26 | $375 |
| AbbVie(2 entities) | 15 | $264 |
| Amarin Pharma, Inc. | 18 | $261 |
| Novo Nordisk | 17 | $261 |
| Amgen | 12 | $238 |
| Boehringer Ingelheim | 10 | $199 |
| Sanofi-aventis U.S. LLC | 6 | $144 |
| Novartis | 8 | $133 |
| Pfizer | 6 | $98 |
| Biohaven Pharmaceuticals, Inc. | 3 | $85 |
| Radius Health, Inc. | 4 | $67 |
| Mayne Pharma Commercial LLC | 1 | $59 |
| Exact Sciences | 3 | $59 |
| Merck | 4 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Astellas Pharma US Inc | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Biogen | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Abbott | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Medicure Pharma Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Organon | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANORO ELLIPTA$300
How this compares
$5,503 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $122,379 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $58,860 |
| MyrbetriqMirabegron | 46 | $46,648 |
| GlyxambiEmpagliflozin/Linagliptin | 32 | $43,013 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $39,153 |
| EliquisApixaban | 56 | $36,258 |
| JardianceEmpagliflozin | 40 | $34,350 |
| TradjentaLinagliptin | 28 | $27,875 |
| XareltoRivaroxaban | 18 | $25,559 |
| NamzaricMemantine Hcl/Donepezil Hcl | 16 | $24,174 |
| JanuviaSitagliptin Phosphate | 26 | $20,676 |
| VascepaIcosapent Ethyl | 38 | $20,639 |
| MounjaroTirzepatide | 13 | $20,422 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 19 | $19,208 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $15,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimGlyxambi, Synjardy Xr, Jardiance, Tradjenta, Trijardy Xr | $199 | $163,599155 claims |
| Novo NordiskOzempic | $261 | $122,379113 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $493 | $72,726103 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $46,64846 claims |
| PfizerEliquis | $98 | $36,25856 claims |
| AbbVieNamzaric, Synthroid | $264 | $29,738161 claims |
| Johnson & JohnsonXarelto | $375 | $25,55918 claims |
| MerckJanuvia, Dulera | $55 | $24,21837 claims |
| Lilly USA, LLCMounjaro | $385 | $20,42213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Angelo
- Darrell HerringtonSan Angelo$8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.